Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- T and its subsidiary, Torii Pharmaceutical, receive rights to develop and commercialize tapinarof for psoriasis and atopic dermatitis in Japan
- Dermavant to receive an upfront payment of $60?million, additional pre-commercial milestone payments of up to $53?million, and sales royalties
- Tapinarof is an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA) currently in Phase 3 development in the U.S. with topline data expected in 2020